Timber Pharmaceuticals, Inc. (TMBR): Price and Financial Metrics
TMBR Price/Volume Stats
| Current price | $0.35 | 52-week high | $3.39 |
| Prev. close | $0.34 | 52-week low | $0.32 |
| Day low | $0.35 | Volume | 26,307 |
| Day high | $0.35 | Avg. volume | 511,937 |
| 50-day MA | $2.43 | Dividend yield | N/A |
| 200-day MA | $2.11 | Market Cap | 1.21M |
TMBR Stock Price Chart Interactive Chart >
Timber Pharmaceuticals, Inc. (TMBR) Company Bio
Timber Pharmaceuticals, Inc. operates as a biotech company. The Company develops treatments for rare skin diseases. Timber Pharmaceuticals serves customers in the State of New Jersey.
Latest TMBR News From Around the Web
Below are the latest news stories about TIMBER PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TMBR as an investment opportunity.
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing ComplianceWARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the “NYSE American”) has accepted the Company’s business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) |
Why Is Skillz (SKLZ) Stock Up 20% Today?Skillz (SKLZ) stock is taking off on Monday after the mobile gaming company announced plans for a share repurchase program. |
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?Timber Pharmaceuticals (TMBR) stock is undergoing a rally on Monday after announcing that Leo US is acquiring it in a $36 million deal. |
Timber Pharmaceuticals to be Acquired by LEO PharmaTransaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced that it has entered into a definitive agreement to be acq |
Timber Pharmaceuticals Discloses Communication From NYSE AmericanWARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (the “Notice”) from the NYSE American LLC (“NYSE American” or the “Exchange”) advising the Company is not in compliance with the NYSE American cont |
TMBR Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -87.59% |
| 1-year | -77.56% |
| 3-year | -99.50% |
| 5-year | -99.96% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -90.79% |
| 2021 | -48.86% |
| 2020 | -85.40% |
| 2019 | -84.58% |
Loading social stream, please wait...